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Abstract
Background: Inflammation is associated with most diseases, which makes understanding the mechanisms of inflammation
vitally important.
Methodology/Principal Findings: Here, we demonstrate a critical function of interleukin-32b (IL-32b) in vascular
inflammation. IL-32b is present in tissues from humans, but is absent in rodents. We found that the gene is highly expressed
in endothelial cells. Three isoforms of IL-32, named IL-32a, b, and e, were cloned from human endothelial cells, with IL-32b
being the major isoform. Pro-inflammatory cytokines (TNFa and IL-1b) induced IL-32b expression through NF-kB.
Conversely, IL-32b propagated vascular inflammation via induction of vascular cell adhesion molecules and inflammatory
cytokines. Accordingly, IL-32b increased adhesion of inflammatory cells to activated endothelial cells, a paramount process
in inflammation. These results illustrate a positive feedback regulation that intensifies and prolongs inflammation.
Importantly, endothelial/hematopoietic expression of IL-32b in transgenic mice elevated inflammation and worsened sepsis.
This was demonstrated by significant elevation of leukocyte infiltration and serum levels of TNFa and IL-1b, increased
vascular permeability and lung damage, and accelerated animal death. Together, our results reveal an important function of
IL-32 in vascular inflammation and sepsis development.
Conclusions/Significance: Our results reveal an important function of IL-32 in vascular inflammation and sepsis
development.
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Introduction
Inflammation is a protective mechanism elicited by the host in
responsetoinfection,injury,andtissuedamage.Itiscloselyassociated
with the development and progression of a variety of diseases.
Vascular endothelium is an active participant in inflammation [1,2].
Inflamed endothelium mediates diverse activities that include the
regulation of leukocyte recruitment and infiltration, cytokine
production, and vascular permeability [3]. During inflammation
initiation, circulating leukocytesmust firstbeabletoadhere selectively
and efficiently to vascular endothelium. This process is facilitated by
induction of vascular cell adhesion molecules on the inflamed
endothelium, such as vascular cell adhesion molecule (VCAM)-1,
intercellular adhesion molecule (ICAM)-1, and E-selectin [1,2]. It is
evident that the endothelium is a critical gatekeeper that controls the
recruitment of distinct leukocyte subpopulations and, in doing so,
determines the nature and extent of acute and chronic inflammation.
Endothelium also exerts a potent inflammatory role by secreting
inflammatory cytokines, such as IL-1 and TNFa, which upregulate
ICAM-1 expression and enhance leukocyte adherence to the
activated endothelium [1,2].
NK4 was originally isolated from activated human natural killer
cells [4]. Its expression is increased upon activation of NK cells by
IL-2 or activation of T cells by mitogens. This gene was
rediscovered in human lymphocytes, and renamed IL-32 [5].
Although IL-32 does not share sequence homology with any
known cytokine families, IL-32 induces various cytokines, such as
TNFa and IL-8 in lymphocytes and monocytic cells [5]. The full
length IL-32 gene is composed of 705 base pairs. IL-32 exists as
four splice variants in blood cells, named IL-32a, b, c and d, with
IL-32a as the major isoform in hematopoietic cells [5]. The
highest homology to human IL-32 was found in equine tissue at
31.8%, and no homologue to this gene was found in mice. Since
IL-32 expression is regulated by inflammatory cytokines in human
peripheral lymphocyte cells, it has been speculated that it may play
a role in inflammatory/autoimmune diseases [5]. Further analysis
indeed showed an elevation of IL-32 in human inflammatory
diseases, such as in rheumatoid arthritis [6,7], ulcerative colitis and
Crohn’s disease [8].
Here, we report a new function of IL-32 in vascular
inflammation and sepsis development. We found that IL-32b
is highly expressed in human endothelial cells. IL-32b amplifies
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9458and sensitizes vascular inflammation through induction of
inflammatory cytokines and cell adhesion molecules, and
subsequently leukocyte adhesion. Importantly, endothelial/
hematopoietic expression of human IL-32b in transgenic mice
elevated inflammation and worsened sepsis. Thus, this study




All animal studies have been conducted according to Animal
Welfare Act and the Public Health Service Policy. The animals
were housed in pathogen-free units at Vanderbilt University
Medical Center, in compliance with IACUC regulations.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) and human
coronary artery endothelial cells (HCAECs), and human aortic
smooth muscle cells (HASMCs) were purchased from Clonetics
(San Diego, CA). Human breast epithelial cells (MCF-7), human
colon epithelial cells (HT29), human lung epithelial cells (H460),
human glioma cells (U251MG), human prostate epithelial cells
(DU145), human embryonic kidney epithelial cells (HEK293),
human fibroblast cells (CCD21-SK), human myeloblastic cells
(HL60), and human monocytes (THP-1) were purchased from
ATCC. Adenoviral vectors directing the expression of IkB
(AdIkBa), a mutated IkB as a NF-kB inhibitor, and GFP (AdGFP)
as viral vector controls were used [9,10].
IL-32 cDNA Synthesis and Cloning
The cDNAs were synthesized from cultured HUVECs. The
cDNAs were used to amplify IL-32 using the specific primer set:
GGGAATTCATGTGCTTCCCGAAGGTC and GGCTCG-
AGTCATTTTGAGGATTGGGG. PCR products were cloned
into pAdTrack-CMV and packaged with pAdEasy-1 for adeno-
virus preparation (AdIL-32b).
Northern Blot
Cells were infected with adenoviral vectors expressing genes of
interest for 48 hour. Cells were then serum starved for 5 hours,
followed by treatment with IL-1b or TNF-a (R D Systems) at
10 ng/ml. RNA was subjected to Northern blot analysis.
32P
labeled cDNA probes for IL-32 mRNA were hybridized using
Express Hyb (BD Biosciences).
q RT-PCR
Total RNA was isolated from HUVECs infected with either
AdGFP or AdIL-32b for 48 hours and from mouse lung endothelial
cells and BM. The primer sets are: ICAM-1 CCACAGTCACC-
Figure 1. IL-32 is highly expressed in vascular endothelial cells. HUVECs were stimulated with or without IL-1b at 10 ng/ml for 24 hours.
Total RNA were isolated and analyzed by Northern blot for IL-32 (Panel A). Cells were treated with or without IL-1b at 10 ng/ml for 24 hours. Total
RNAs isolated from different types of human cells were analyzed by Northern blot for IL-32 (Panel B). 18S & 28S rRNA were used as a loading control.
doi:10.1371/journal.pone.0009458.g001
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CCTGATCG/ATCACTCCAAAGTGCAGCAG, and IL-32 CG-
ACTTCAAAGAGGGCTACC/GAGTGAGCTCTGGGTGCT-
G. Relative levels of IL-32 mRNA in IL-32 transgenic mouse was
calculated by subtracting the wild type value from the value in the
transgenic mouse. We assume the reading in wild type mouse as zero
since IL-32 is absent in rodent.
Transfection
HUVECs were transfected with IL32 shRNA target plasmid set
(Sigma-Aldrich) using transfection kit (Amaxa). One shRNA
(#59213) in the target set does not target any genes, and it was
used as a control.
Cell Adhesion Assay
HUVECs were infected with either AdGFP or AdIL-32b, then
treated with recombinant IL-1b for 4 hours. THP-1 cells were
labeled with PKH26 Red Fluorecent Cell Liner kit (Sigma-
Aldrich) and allowed to adhere to the monolayer of HUVECs for
30 min. Adhered THP-1 cells were counted under fluorescent
microscopy. Similarly, microvascular endothelial cells were
isolated from mouse lungs as described [11], and subjected to
cell adhesion assay.
IL-32 Transgenic Mice
We constructed a plasmid in which IL-32b human transgene is
driven by an endothelial/hematopoietic specific, platelet endothe-
lial cell adhesion molecule-1 (PECAM-1) promoter, which was
kindly provided by Dr. HS Baldwin at Vanderbilt. Using the
plasmid, a transgenic mouse line was generated in FVB
background at the Vanderbilt Transgenic Mouse Core.
CLP Model
Ten weeks old mice were used for the cecal-ligation and
puncture (CLP) model as described [12]. Seventeen hours after
CLP, mice were sacrificed and blood was drawn. Serum
concentrations of IL-1b and TNFa were measured using
commercial ELISA kits (R & D system). Lung tissues were
harvested and embedded in paraffin. Histological sections were
stained with H&E.
A dorsal skin window was established in the back skin fold of a
mouse as described for 24 hours [13], followed by the CLP
procedure. Six hours after the CLP, 1 mg of dextran tetra-
methylrhodamine (10,000 MW) in 100 ul saline was injected via
tail vein. Vasculature was imaged through the window chamber
using fluorescent microscopy.
Statistics
Results are reported as mean 6 SEM. Statistical analysis was
done using a two-tailed Student’s t-test. Differences were
considered statistically significant at p,0.05. Sepsis study was
graphed in Kaplan-Meier format and analyzed by a log-rank test.
Results
IL-32 Is Highly Expressed in Vascular Endothelial Cells
In searching for Akt target genes in human endothelial cells, we
identified NK4, which was recently renamed IL-32 [5]. Sequence
analysis identified three isoforms of IL-32, which are 489 bp (IL-
32a); 567 bp (IL-32b); and 507 bp (IL-32e). Among them, IL-32b
is the major isoform in endothelial cells.
As IL-32 is reportedly ubiquitously expressed in human tissues
[5], we next compared the expression of IL-32 in different types of
human cells, including endothelial cells, epithelial cells, smooth
muscle cells, fibroblast cells and leukocytes. Interestingly, we found
a high level expression of IL-32 in endothelial cells, including large
and small vascular endothelial cells, with minimum or undetect-
able levels in most non-endothelial cells (Figure 1).
IL-1b and TNFa Induce IL-32b Expression in an NF-kB
Dependent Manner
To investigate the function of IL-32b in endothelial biology, we
studied gene regulation. We found that inflammatory cytokines
dramatically induced IL-32b expression in cultured human
endothelial cells (Figure 1, Figure 2A and 2B), suggesting a role
of IL-32b in vascular inflammation. As NF-kB is a master
mediator that regulates the expression of a variety of genes
involved in inflammation; we examined its role in IL-32b gene
expression. We found that NF-kB activity is essential for IL-32b
expression in response to inflammatory cytokine stimulation.
Blocking NF-kB function using a mutant IkB [9] completely
abolished TNFa- and IL-1-induced IL-32b expression in endo-
thelial cells (Figure 2A and 2B). Furthermore, NF-kB activity is
also required for basal level expression of IL-32b, as there is no
detectable amount of the gene in mutant IkB treated group
compared to noticeable expression in unstimulated cells.
IL-32b Amplifies Vascular Inflammation via the
Production of Inflammatory Cytokines and Vascular Cell
Adhesion Molecules, and Subsequent Adhesion of
Leukocytes
Next, we investigated the molecular mechanism of IL-32b in
vascular inflammation. The expression of cell adhesion molecules,
Figure 2. Inflammatory cytokines induce IL-32 expression via
NF-kB. HUVECs were infected with control Adb-gal or AdIkB
adenovirus (MOI=10) for 36 hours, followed by incubation with
recombinant IL-1b (Panel A) or TNFa (Panel B) at 10 ng/ml for 12 hours.
Uninfected cells were used as a control (none). IL-32 mRNA was
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endothelium is an initial and critical event in inflammation. We
found that expression of IL-32b (5.4 6 0.1 fold increase over GFP
control) alone had no effects on the expression of cell adhesion
molecules. However, it significantly increased cellular responses to
a very low dose of IL-1b stimulation (Figure 3A, 3B and 3C).
Further analysis revealed that the level of IL-32 mRNA is
approximately 3.1 fold and 11.3 fold higher in IL-1b stimulated
control vector transfected and IL-32b vector transfected cells than
corresponding non-stimulated cells, respectively. Although we only
achieved 25.9 6 3.5% knockdown of basal levels IL-32, the
reduction was significant and most importantly it totally blocked
IL-1 induced IL-32 gene expression (Figure 3D). Consistently,
blocking IL-32 induction in endothelial cells using shRNA
significantly attenuated IL-1b induced expression of cell adhesion
molecules (Figure 3E, 3F and 3G). Accordingly, an analysis of
leukocyte adhesion on stimulated endothelial cells demonstrated
that significantly increase of leukocytes adhered to IL-32b
Figure 3. IL-32b increases the expression of vascular cell adhesion molecules and subsequent leukocyte adhesion. HUVECs were
infected with either AdIL-32b or AdGFP vector for 48 hours, and then treated with IL-1b at 100 pg/ml for 4 hours. qRT-PCR was performed for the
indicated cell adhesion molecules. Each gene was normalized with b-actin. Fold change of gene expression was calculated against the GFP/IL-1 (Panel
A-C). HUVECs were transfected with IL32 shRNA target plasmid or control shRNA plasmid, followed by treatment with IL-1b for 48 hours. qRT-PCR was
performed for the indicated IL-32 and cell adhesion molecules. Fold change of gene expression was calculated against the shCNT treated group
(Panel D-G). HUVECs were infected with either control AdGFP or AdIL-32b for 36 hours, followed by incubation with IL-1b at the dose indicated for
4 hours. THP-1 leukocyte adhesion was measured 30 minutes after incubation and counted under microscopy (Panel H). All the experiments were
repeated at least 3 times. The data are presented as mean 6 SEM. *p,0.05.
doi:10.1371/journal.pone.0009458.g003
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IL-32b sensitizes endothelial cells and/or amplifies vascular
inflammation through elevated expression of cell adhesion
molecules and subsequent leukocyte adhesion on activated
vascular endothelium.
In addition to cell adhesion molecule expression, endothelium is
also a major source of cytokine production during inflammation.
One of the interesting features of pro-inflammatory cytokines is
that they induce their own expression, and thus propagate and
prolong inflammatory signals. To test this role of IL-32b,w e
transfected HUVECs with either an IL-32b expression vector or
an empty vector for 24 hours, followed by stimulation with a sub
dose of IL-1b. We detected a 2.2 fold (95% CI; 1.1, 4.7) increase in
IL-1b mRNA levels in IL-32b vector transfected cells compared to
controls. Collectively, these data suggest a positive feedback
mechanism, in which inflammatory cytokines induce IL-32b
expression, and IL-32b further amplifies cytokine-induced inflam-
matory responses through increased leukocyte adhesion, as well as
increased production of pro-inflammatory cytokines. As a result,
inflammation may be intensified.
IL-32b Promotes Inflammation and Exacerbates Sepsis In
Vivo
One of the interesting and unique features of IL-32 is its
absence in mice. To further characterize the function of IL-32b
in inflammation in vivo, we generated a transgenic mouse line
(PECAM-IL32), in which IL-32b is driven by an endothelial/
hematopoietic cell specific promoter, the PECAM-1 promoter
[14]. PECAM-IL32 transgenic mice are grossly healthy, viable
and fertile. Vascular endothelial transgene expression was
verified using microvascular endothelial cells isolated from
lungs of transgenic mice (Figure 4A). Accordingly, there is
a significant increase in leukocyte adhesion on lung endo-
thelial cells isolated from the transgenic mice compared to
t h o s ef r o mw i l dt y p el i t t e r m a t e s(Figure 4B), consistent with the
in vitro data and supporting a role of IL-32b in vascular
inflammation.
Sepsis is a systemic inflammatory response to bacterial infection.
Widespread inflammation causes rapid changes in body temper-
ature, blood pressure, and vascular permeability, and dysfunction
in the lungs and other organs, often leading to death. Thus, we
tested the function of IL-32b in inflammation using a cecal-ligation
and puncture (CLP) sepsis model. As expected, animal death was
significantly accelerated in PECAM-IL32 mice compared to wild
type mice (p=0.03) (Figure 5). Consistently, we observed a
dramatic increase of TNFa and IL-1b serum levels in the IL-32
transgenic mice (p,0.01) (Figure 6A and 6B), a significant increase
in inflammatory cell infiltration, edema, thickening of the alveolar
wall and severe tissue damage in lungs of the PECAM-IL32 mice
compared to the ones from the wild type mice (Figure 6C). We
also found significantly higher levels of neutrophil infiltration in
lungs of PECAM-IL-32 mice than in wild type controls
(Figure 6D). These phenotypes are consistent with the clinical
observations in septic patients.
Increased vascular leakiness is a hallmark of sepsis. To examine
the effects of IL-32b on vascular permeability during sepsis
development, we placed a vascular window chamber in the back
skin fold of a mouse prior to the CLP procedure. Six hours after
the CLP, rhodamine-dextran conjugate was intravenously inject-
ed, and vascular leakiness was directly imaged in live mice. There
is a clear increase in blood vessel dilation and vascular leakiness in
IL-32 transgenic mice compared to wild type controls (Figure 6E).
Figure 4. Characterization of PECAM-IL32 transgenic mice. Microvascular endothelial cells were isolated from lungs of PECAM-IL32 mice and
wild type littermates. The level of IL-32b expression was determined Western blot (Panel A). Freshly isolated lung vascular endothelial cells from
multiple wild type or PECAM-IL32 mice were treated with IL-1b at 100 pg/ml or vehicle control for 4 hours. THP-1 leukocyte adhesion was measured
30 minutes after incubation and counted under microscopy (Panel B). The experiment was repeated at least three times. *p,0.05.
doi:10.1371/journal.pone.0009458.g004
Figure 5. Over-expression of IL-32b in vivo accelerates animal
death under septic conditions. The cecal-ligation and puncture
model was used to induce sepsis in wild type and PECAM-IL32 mice.
Survival curve is presented. n=12 for each group.
doi:10.1371/journal.pone.0009458.g005
IL-32 Regulates Sepsis
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of IL-32b in vascular inflammation. IL-32b amplifies and
propagates inflammatory reactions that worsen sepsis and lead
to animal death.
Discussion
Vascular inflammation plays a critical role in pathological
conditions [1,2,3]. In this study, we identify a new function of IL-
32b in vascular inflammation. We show that IL-32b is highly
expressed in vascular endothelial cells, and pro-inflammatory
cytokines upregulate its expression in a NF-kB dependent
manner. This finding is consistent with a recent publication in
endothelial cells [15]. IL-32b sensitizes/amplifies inflammatory
cytokine mediated expression of cell adhesion molecules, as well
as the expression of those same cytokines. Accordingly, it
enhances leukocyte adhesion on inflamed endothelium. These
data illustrate a positive feedback mechanism, in which
inflammatory cytokines induce IL-32b expression, and subse-
quently IL-32b increases cellular responses to propagate the
Figure 6. Over-expression of IL-32b in vivo increases inflammation and exacerbates sepsis. Seventeen hours after the CLP procedure,
TNFa and IL-1b levels in serum were measured by ELISA. *p,0.05. n=5 mice for each group (Panel A and B). At the same time, lung tissues sections
were stained with H&E. Representative images (200X) are shown (Panel C). Infiltrating neutrophils were counted in ten randomly selected high power
fields (200X) and graphed (Panel D). n=5 mice per group, *p,0.05. A vascular window chamber was installed on the back skin fold of mouse for
24 hours, followed by the CLP procedure or sham operation. Dextran tetramethylrhodamine (10,000 MW) at 1 mg in 100 ul saline was injected via
tail vein 6 hours after the CLP procedure. Vasculature was imaged through the window chamber under a fluorescent microscope (Panel E).
Representative images were shown. n=4 mice per group.
doi:10.1371/journal.pone.0009458.g006
IL-32 Regulates Sepsis
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leukocytes to inflamed endothelium, as well as pro-inflammatory
cytokines. As a result, inflammation is amplified and prolonged
(Figure 7). Interestingly, one study has demonstrated an IL-32-
mediated degradation of IkB in lymphocytes [5], which could
add another level to the positive regulation of inflammatory
responses. Most importantly, endothelial/hematopoietic expres-
sion of human IL-32b in transgenic mice intensified inflammation
and exacerbated sepsis. Considering inflammation is a risk factor
for a variety of diseases, this study could have important
implications in sepsis and other diseases.
One of the features of IL-32 that drew our attention is the fact
that IL-32 does not exist in the rodent genome or published
genomic libraries of other species. A similar search performed for
IL-32 using the NCBI databank showed the highest homology
(31.8%) with human in equine IL-32 (AC: CD469554 and
BI961524) [5]. It was followed by bovine (AC: CK832489), ovine
(AC: CO202364), and swine (AC: CB287292). These findings led
us to examine gene expression, and we found that IL-32 is
expressed in humans and certain primates (data not shown). This
result suggests IL-32 may be a ‘‘human/primate specific gene’’.
Interestingly, mice are commonly used as model systems to study
human diseases. However, we often observe reduced or attenuated
inflammatory responses in rodent disease models compared to
human conditions. Therefore, an understanding of the differences
at the genetic level between us and rodents could have major
implications on our health.
An analysis of B cells from 18 individuals revealed variable
banding patterns suggestive of polymorphism within the NK4
gene [4]. In this study, we cloned three different spliced isoforms
of IL-32 in endothelial cells, IL-32a,I L - 3 2 b and IL-32e,w i t hI L -
32b being the dominant isoform in endothelial cells. Recently,
several isoforms of IL-32 were reported in lymphocytes, which
include IL-32a,I L - 3 2 b, and IL-32c (full length), and IL-32d in
N Kc e l l s[ 5 ] ,a sw e l la sI L - 3 2 b,I L - 3 2 d,I L - 3 2 e, and IL-32f in T
cells [16]. IL-32a was shown to be the major isoform in NK cells
[5], whereas IL-32b was predominant in T cells [16] and
endothelial cells. Nold-Petry et al showed a switch of isoforms
from IL-32a and IL-32c to IL-32b and IL-32e to some degree in
HUVECs upon IL-1b treatment [15]. These findings indicate
that IL-32 is processed differently in different types of cells, and
different isoforms may function differently in each cell type. It
would be interesting to determine the functions of each isoform in
each type of cells.
The vascular network, being the interface of two compartments
(blood and tissues), plays a key role in inflammation. The
interaction of inflammatory cells with inflamed endothelium is
an initial and paramount process in inflammation. In this study,
we show that IL-32b amplifies inflammatory cytokine mediated
vascular inflammation. IL-32b alone has no or minimal effects on
the expression of cell adhesion molecules and pro-inflammatory
cytokines in endothelium. However, IL-32b enhances the cellular
response to very low dose of cytokine stimulation, which results in
enhanced leukocyte adhesion. These results imply that IL-32b
itself is not a cytokine, but it amplifies and sensitizes the cellular
response to cytokine stimulation. This result is consistent with our
recent publication, in which we showed that IL-32b is not a
secreted protein rather an intracellular protein localized in the ER
[17].
To investigate the function of IL-32b in vivo, we generated a
t r a n s g e n i cm o u s el i n eu s i n gt h eP E C A M - 1p r o m o t e r .P E C A M -
1 is only expressed in endothelium and hematopoietic cells
[14,18]. PECAM-1 promoter has been used to express
transgene in endothelial/hematopoietic cells. Although using
this promoter may not allow us to pin point the direct
contribution of endothelial IL-32 in vascular inflammation in
vivo, but it is also advantageous, simply because it reflects high
levels endogenous IL-32 expression in endothelial and hemato-
poietic cells. There are a few other promoters that are deemed
‘‘endothelial specific’’, such as the Tie2 promoter. However,
emerging data suggest Tie2 is also expressed in hematopoietic
cells, such as monocytes [19]. The same story goes for the
VEGF receptor 2, another so called ‘‘endothelial specific’’ gene.
These expression patterns reflect a common origin between
hematopoietic cells and endothelial cells.
Sepsis is a systemic inflammatory reaction, and severe sepsis
often leads to death. The cause of sepsis is not the infection itself,
but rather the host inflammatory response. Endothelium dysfunc-
tion is one of the hallmarks of sepsis [20]. When production of the
inflammatory mediators and phenotypic alterations are uncon-
trolled and excessive, this leads to vascular and tissue damage,
organ dysfunction and death. Consistent with the in vitro data, we
demonstrate that endothelial/hematopoietic expression of human
IL-32b in mice increased inflammatory cell infiltration, vascular
leakiness and tissue damage in lungs that resulted in a significant
acceleration of animal death compared to wild type control.
Serum TNFa and IL-1b levels, two primary mediators of septic
shock, are significantly increased in these mice as well. These
results suggest IL-32b as a positive mediator in sepsis development.
In addition to our findings on vascular inflammation and sepsis,
IL-32 has been implicated in inflammatory diseases. Injection of
recombinant human IL-32c in mouse knee joints caused
rheumatoid arthritis-like symptoms [6], and overexpression of
human IL-32b mouse bone marrow cells exacerbated collagen-
induced arthritis and trinitrobenzen sulfonic acid-induced colitis
[7].
In summary, this study has identified a critical function of IL-
32b in vascular inflammation and sepsis development. Consider-
ing the close association of inflammation with human disease, and
that IL-32 seems to be a ‘‘human/primate specific gene’’,
understanding the function of IL-32 could have a significant
impact on our health. Of additional note, the IL-32b transgenic




PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9458mice may offer a better and more relevant system for studying
human diseases, as we often observe partial and reduced
phenotypes in rodent disease models compared to humans.
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